-
2
-
-
0016756272
-
Continuous cultures of fused cells secreting antibody of predefined specificity
-
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-497
-
(1975)
Nature
, vol.256
, Issue.5517
, pp. 495-497
-
-
Kohler, G.1
Milstein, C.2
-
3
-
-
2942591945
-
The cancer/testis genes: Review, standardization, and commentary
-
Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 4:1
-
(2004)
Cancer Immun
, vol.4
, pp. 1
-
-
Scanlan, M.J.1
Simpson, A.J.2
Old, L.J.3
-
4
-
-
0022502868
-
Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney
-
Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J et al (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38(4):489-494
-
(1986)
Int J Cancer
, vol.38
, Issue.4
, pp. 489-494
-
-
Oosterwijk, E.1
Ruiter, D.J.2
Hoedemaeker, P.J.3
Pauwels, E.K.4
Jonas, U.5
Zwartendijk, J.6
-
5
-
-
0021978357
-
Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer
-
Finstad CL, Cordon-Cardo C, Bander NH, Whitmore WF, Melamed MR, Old LJ (1985) Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci USA 82(9):2955-2959
-
(1985)
Proc Natl Acad Sci USA
, vol.82
, Issue.9
, pp. 2955-2959
-
-
Finstad, C.L.1
Cordon-Cardo, C.2
Bander, N.H.3
Whitmore, W.F.4
Melamed, M.R.5
Old, L.J.6
-
6
-
-
0024378807
-
Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas
-
Bander NH, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED Jr, Whitmore WF Jr et al (1989) Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res 49(23):6774-6780
-
(1989)
Cancer Res
, vol.49
, Issue.23
, pp. 6774-6780
-
-
Bander, N.H.1
Finstad, C.L.2
Cordon-Cardo, C.3
Ramsawak, R.D.4
Vaughan Jr., E.D.5
Whitmore Jr., W.F.6
-
7
-
-
0022353525
-
Monoclonal antibodies to human renal cell carcinoma: Recognition of shared and restricted tissue antigens
-
Vessella RL, Moon TD, Chiou RK, Nowak JA, Arfman EW, Palme DF et al (1985) Monoclonal antibodies to human renal cell carcinoma: Recognition of shared and restricted tissue antigens. Cancer Res 45(12 Pt 1):6131-6139
-
(1985)
Cancer Res
, vol.45
, Issue.12 PART 1
, pp. 6131-6139
-
-
Vessella, R.L.1
Moon, T.D.2
Chiou, R.K.3
Nowak, J.A.4
Arfman, E.W.5
Palme, D.F.6
-
8
-
-
0022532574
-
Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma
-
Oosterwijk E, Ruiter DJ, Wakka JC, Huiskens-van der Meij JW, Jonas U, Fleuren GJ et al (1986) Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma. Am J Pathol 123(2):301-309
-
(1986)
Am J Pathol
, vol.123
, Issue.2
, pp. 301-309
-
-
Oosterwijk, E.1
Ruiter, D.J.2
Wakka, J.C.3
Huiskens-van der Meij, J.W.4
Jonas, U.5
Fleuren, G.J.6
-
9
-
-
0028897420
-
Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis
-
Gnarra JR, Lerman MI, Zbar B, Linehan WM (1995) Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22(1):3-8
-
(1995)
Semin Oncol
, vol.22
, Issue.1
, pp. 3-8
-
-
Gnarra, J.R.1
Lerman, M.I.2
Zbar, B.3
Linehan, W.M.4
-
10
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593-4599
-
(1997)
Cancer Res
, vol.57
, Issue.20
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
Chisholm, V.4
Meng, Y.G.5
Krummen, L.6
-
11
-
-
11844254414
-
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
-
Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62
-
(2005)
Science
, vol.307
, Issue.5706
, pp. 58-62
-
-
Jain, R.K.1
-
12
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427-434
-
(2003)
N Engl J Med
, vol.349
, Issue.5
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
Hwu, P.4
Schwartzentruber, D.J.5
Topalian, S.L.6
-
13
-
-
35549006672
-
A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma
-
(June Supplement)
-
Escudier B, Koralewski A, Pluzanska A, Ravaud S, Bracarda C, Szczylik C et al. (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol, 2007 ASCO annual meeting proceedings part 1, vol 25, no 18S (June Supplement):3
-
(2007)
J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part 1
, vol.25
, Issue.18 S
, pp. 3
-
-
Escudier, B.1
Koralewski, A.2
Pluzanska, A.3
Ravaud, S.4
Bracarda, C.5
Szczylik, C.6
-
14
-
-
30944452354
-
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
-
Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23(31):7889-7896
-
(2005)
J Clin Oncol
, vol.23
, Issue.31
, pp. 7889-7896
-
-
Hainsworth, J.D.1
Sosman, J.A.2
Spigel, D.R.3
Edwards, D.L.4
Baughman, C.5
Greco, A.6
-
15
-
-
33750938968
-
Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC)
-
(June 20 Supplement)
-
Bukowski RM, Kabbinavar F, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U et al (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol, 2006 ASCO annual meeting proceedings part I, vol 24, no 18S (June 20 Supplement):4523
-
(2006)
J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I
, vol.24
, Issue.18 S
, pp. 4523
-
-
Bukowski, R.M.1
Kabbinavar, F.2
Figlin, R.A.3
Flaherty, K.4
Srinivas, S.5
Vaishampayan, U.6
-
16
-
-
39149083925
-
A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
-
(June 20 Supplement)
-
Garcia JA, Rini BI, Mekhail T, Triozzi P, Elson C, Nemec C et al (2007) A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol, 2007 ASCO annual meeting proceedings part I, vol 25, no 18S (June 20 Supplement): 15586
-
(2007)
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I
, vol.25
, Issue.18 S
, pp. 15586
-
-
Garcia, J.A.1
Rini, B.I.2
Mekhail, T.3
Triozzi, P.4
Elson, C.5
Nemec, C.6
-
17
-
-
37149006085
-
A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors
-
(June 20 Supplement)
-
Cooney MM, Garcia JBJ, Dreicer R, Beatty K, Mekhail T, Bukowski R et al (2007) A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. J Clin Oncol, 2007 ASCO annual meeting proceedings part I, vol 25, no 18S (June 20 Supplement):15532
-
(2007)
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I
, vol.25
, Issue.18 S
, pp. 15532
-
-
Cooney, M.M.1
Garcia, J.B.J.2
Dreicer, R.3
Beatty, K.4
Mekhail, T.5
Bukowski, R.6
-
18
-
-
36749098248
-
Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
-
(June 20 Supplement)
-
Merchan JR, Liu G, Fitch T, Picus J, Qin R, Pitot HC et al. (2007) Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol, 2007 ASCO annual meeting proceedings part I, vol 25, no 18S (June 20 Supplement):5034
-
(2007)
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I
, vol.25
, Issue.18 S
, pp. 5034
-
-
Merchan, J.R.1
Liu, G.2
Fitch, T.3
Picus, J.4
Qin, R.5
Pitot, H.C.6
-
19
-
-
0032886302
-
MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
-
Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y et al (1999) MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81(4):741-746
-
(1999)
Br J Cancer
, vol.81
, Issue.4
, pp. 741-746
-
-
Uemura, H.1
Nakagawa, Y.2
Yoshida, K.3
Saga, S.4
Yoshikawa, K.5
Hirao, Y.6
-
20
-
-
0034671307
-
Hypoxia-inducible expression of tumor-associated carbonic anhydrases
-
Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A et al (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60(24):7075-7083
-
(2000)
Cancer Res
, vol.60
, Issue.24
, pp. 7075-7083
-
-
Wykoff, C.C.1
Beasley, N.J.2
Watson, P.H.3
Turner, K.J.4
Pastorek, J.5
Sibtain, A.6
-
21
-
-
0034099829
-
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
-
Grabmaier K, Vissers JL, de Weijert MCA, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH et al (2000) Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85(6):865-870
-
(2000)
Int J Cancer
, vol.85
, Issue.6
, pp. 865-870
-
-
Grabmaier, K.1
Vissers, J.L.2
de Weijert, M.C.A.3
Oosterwijk-Wakka, J.C.4
Van Bokhoven, A.5
Brakenhoff, R.H.6
-
22
-
-
3342967945
-
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma
-
Grabmaier K, de Weijert AMC, Verhaegh GW, Schalken JA, Oosterwijk E (2004) Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23(33):5624-5631
-
(2004)
Oncogene
, vol.23
, Issue.33
, pp. 5624-5631
-
-
Grabmaier, K.1
de Weijert, A.M.C.2
Verhaegh, G.W.3
Schalken, J.A.4
Oosterwijk, E.5
-
23
-
-
0027462558
-
Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250
-
Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD et al (1993) Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J Clin Oncol 11(4):738-750
-
(1993)
J Clin Oncol
, vol.11
, Issue.4
, pp. 738-750
-
-
Oosterwijk, E.1
Bander, N.H.2
Divgi, C.R.3
Welt, S.4
Wakka, J.C.5
Finn, R.D.6
-
24
-
-
0031724558
-
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
-
Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S et al (1998) Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4(11):2729-2739
-
(1998)
Clin Cancer Res
, vol.4
, Issue.11
, pp. 2729-2739
-
-
Divgi, C.R.1
Bander, N.H.2
Scott, A.M.3
O'Donoghue, J.A.4
Sgouros, G.5
Welt, S.6
-
25
-
-
17544404888
-
Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250
-
Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB et al (1997) Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 15(4):1529-1537
-
(1997)
J Clin Oncol
, vol.15
, Issue.4
, pp. 1529-1537
-
-
Steffens, M.G.1
Boerman, O.C.2
Oosterwijk-Wakka, J.C.3
Oosterhof, G.O.4
Witjes, J.A.5
Koenders, E.B.6
-
26
-
-
0032694512
-
Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250
-
Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA et al (1999) Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5(10 Suppl):3268s-3274s
-
(1999)
Clin Cancer Res
, vol.5
, Issue.10 SUPPL.
-
-
Steffens, M.G.1
Boerman, O.C.2
de Mulder, P.H.3
Oyen, W.J.4
Buijs, W.C.5
Witjes, J.A.6
-
27
-
-
4544260382
-
Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer
-
Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ et al (2004) Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45(8):1412-1421
-
(2004)
J Nucl Med
, vol.45
, Issue.8
, pp. 1412-1421
-
-
Divgi, C.R.1
O'Donoghue, J.A.2
Welt, S.3
O'Neel, J.4
Finn, R.5
Motzer, R.J.6
-
28
-
-
27244448455
-
Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma
-
Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C et al (2005) Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 23(27):6540-6548
-
(2005)
J Clin Oncol
, vol.23
, Issue.27
, pp. 6540-6548
-
-
Brouwers, A.H.1
Mulders, P.F.2
de Mulder, P.H.3
van den Broek, W.J.4
Buijs, W.C.5
Mala, C.6
-
29
-
-
1542399581
-
Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re
-
Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH et al (2004) Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 45(2):327-337
-
(2004)
J Nucl Med
, vol.45
, Issue.2
, pp. 327-337
-
-
Brouwers, A.H.1
van Eerd, J.E.2
Frielink, C.3
Oosterwijk, E.4
Oyen, W.J.5
Corstens, F.H.6
-
30
-
-
0030017852
-
Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors
-
Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR et al (1996) Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 19(3):184-191
-
(1996)
J Immunother Emphasis Tumor Immunol
, vol.19
, Issue.3
, pp. 184-191
-
-
Surfus, J.E.1
Hank, J.A.2
Oosterwijk, E.3
Welt, S.4
Lindstrom, M.J.5
Albertini, M.R.6
-
31
-
-
11144354471
-
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
-
Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C et al (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90(5):985-990
-
(2004)
Br J Cancer
, vol.90
, Issue.5
, pp. 985-990
-
-
Bleumer, I.1
Knuth, A.2
Oosterwijk, E.3
Hofmann, R.4
Varga, Z.5
Lamers, C.6
-
32
-
-
29144503225
-
A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma
-
Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Voller MC, Melchior S, Warnaar SO et al (2006) A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175(1):57-62
-
(2006)
J Urol
, vol.175
, Issue.1
, pp. 57-62
-
-
Bleumer, I.1
Oosterwijk, E.2
Oosterwijk-Wakka, J.C.3
Voller, M.C.4
Melchior, S.5
Warnaar, S.O.6
-
33
-
-
33947504376
-
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial
-
Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S et al (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 8(4):304-310
-
(2007)
Lancet Oncol
, vol.8
, Issue.4
, pp. 304-310
-
-
Divgi, C.R.1
Pandit-Taskar, N.2
Jungbluth, A.A.3
Reuter, V.E.4
Gonen, M.5
Ruan, S.6
|